Category: GLP-1s

Debates are swirling about surgery disruptions, a baby boom phenomenon and additional uses for Ozempic and other glucagon-like peptide-1 medicines. 

Since summer 2023, physicians have recommended patients taking GLP-1s, such as Ozempic or Mounjaro, to skip a dose before an elective surgery. Researchers from Stanford Medicine say this might be unnecessary and create adverse effects. 

Four more solutions of Zepbound and Mounjaro are in limited supply, and the shortages have prolonged, the FDA said April 17. 

While weight loss drugs have been touted as a game-changer for the nation’s obesity epidemic, many Americans who would benefit most from the medications often lack access, experts told the Los Angeles Times in an April 15 report.

Researchers are expanding horizons for the diseases and disorders that GLP-1s such as Ozempic, Mounjaro and Wegovy could treat.

Physicians and researchers say more data is needed on pregnancy outcomes in patients taking GLP-1s as a growing number of women turn to the class of weight loss medications in hopes of reducing their risk of pregnancy complications or increasing their …

After achieving promising outcomes for patients with sleep apnea, Eli Lilly said April 17 it plans to seek a wider FDA approval for Mounjaro and Zepbound. 

Available evidence does not suggest a link between the use of GLP-1 receptor agonists, including Ozempic and Wegovy, and suicidal thoughts or actions, according to a review from drug regulators in Europe. 

Surprise pregnancies may be an unexpected side effect experienced by women who use Ozempic or other GLP-1 medications, The Washington Post reported April 5.

A small study has found lixisenatide, a GLP-1 made by Sanofi, may slow the progression of Parkinson’s disease, according to findings published April 3 in The New England Journal of Medicine.